Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
4 hedge funds and large institutions have $20K invested in Northwest Biotherapeutics, Inc. Common stock in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
13% less capital invested
Capital invested by funds: $23K → $20K (-$3K)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WJWM
1
Williams Jones Wealth Management
New York
| $11K | – | – | – |
|
|
LDB
2
Lee, Danner & Bass
Nashville,
Tennessee
| $4K | – | – | – |
|
|
MPI
3
Mairs & Power Inc
St Paul,
Minnesota
| $3K | – | – | – |
|
|
OCG
4
Opus Capital Group
Cincinnati,
Ohio
| $2K | – | – | – |
|
|
5
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -6,000 | Closed |
|
NWBO Hedge Fund Activity: Q4 2019 in Review
4 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2019, worth a combined $20K — down 13% from $23K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NWBO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $1K sold.
- 4 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2019, down from 5 in Q3 2019.
- Funds reported $20K of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2019, down 13% quarter-over-quarter.
- 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2019 and 1 closed out, a net change of -1 holder.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2019 was CAPTRUST Financial Advisors, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2019.